MiR-873/PD-L1 axis regulates the stemness of breast cancer cells

被引:119
|
作者
Gao, Lanlan [1 ,2 ]
Guo, Qianqian [1 ,2 ]
Li, Xiaoman [3 ]
Yang, Xuan [1 ,2 ]
Ni, Haiwei [1 ,2 ]
Wang, Ting [1 ,2 ]
Zhao, Qiong [1 ,2 ]
Liu, Hai [1 ,2 ]
Xing, Yingying [1 ,2 ]
Xi, Tao [1 ,2 ]
Zheng, Lufeng [1 ,2 ]
机构
[1] China Pharmaceut Univ, Sch Life Sci & Technol, Nanjing 210009, Peoples R China
[2] China Pharmaceut Univ, Jiangsu Key Lab Carcinogenesis & Intervent, Nanjing 210009, Peoples R China
[3] Nanjing Univ Chinese Med, Sch Pharm, Jiangsu Key Lab Pharmacol & Safety Evaluat Chines, Nanjing 210023, Jiangsu, Peoples R China
来源
EBIOMEDICINE | 2019年 / 41卷
基金
中国博士后科学基金;
关键词
miR-873; PD-L1; Cancer stem cells; Drug resistance; PI3K/Akt; ERK1/2; PD-L1; EXPRESSION; TUMOR-SUPPRESSOR; IFN-GAMMA; TAMOXIFEN RESISTANCE; DRUG-RESISTANCE; TARGETING CDK3; B7-H1; METASTASIS; CHEMORESISTANCE; PROGRESSION;
D O I
10.1016/j.ebiom.2019.02.034
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Breast cancer stem cells have self-renewal capability and are resistant to conventional chemotherapy. PD-L1 could promote the expression of stemness markers (OCT4 and Nanog) in breast cancer stem cells. However, the mechanisms by which PD-L1 regulates the stemness of breast cancer cells and PD-L1 is regulated in breast cancer cells are still unclear. Methods: Lentivirus infectionwas used to construct stable cell lines. The correlation between PD-L1 and stemness markers expression was evaluated in clinical samples. Additionally, luciferase reporter assay combined with RNA-Fluorescence in situ hybridization (RNA-FISH) and RNA-binding protein immunoprecipitation (RIP) assays were used to verify the direct binding of miR-873 on PD-L1. Furthermore, flowcytometry, mammosphere formation combined with nude mouse tumor xenograftmodel were carried out to examine the effects ofmiR-873/PDL1 axis on the stemness of breast cancer cells. Finally, MTT assay was performed to determine the effects of miR873/ PD-L1 axis on drug resistance. Findings: PD-L1 expression was positively correlated with the expression of stemness markers, and overexpression of PD-L1 contributed to chemoresistance and stemness-like properties in breast cancer cells via activating PI3K/Akt and ERK1/2 pathways. Mechanistically, miR-873 inhibited PD-L1 expression through directly binding to its 3'-untranslated region (UTR), and miR-873 attenuated the stemness and chemoresistance of breast cancer cells which was dependent on PD-L1 and the downstream PI3K/Akt and ERK1/2 signaling. Notably, the promotion of PD-L1 on the stemness and chemoresistance was enhanced by recombinant PD-1 (rPD-1), this effect was attenuated by PD-1/PD-L1 inhibitor. Interpretation: miR-873/PD-L1 regulatory axis might serve as a therapeutic target to enhance the chemosensitivity and eliminate the stemness of breast cancer cells. Fund: This work was supported by the National Nature Science Foundation of China, No. 81702957, China Postdoctoral Science Foundation, No. 2017M620230, the Postdoctoral Research Funding Scheme of Jiangsu Province (2017), No. 1701197B, and the Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions. (c) 2019 The Authors. Published by Elsevier B. V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:395 / 407
页数:13
相关论文
共 50 条
  • [1] MiR-873/PD-L1 axis regulates the stemness of breast cancer cells (vol 41, pg 395, 2019)
    Gao, Lanlan
    Guo, Qianqian
    Li, Xiaoman
    Yang, Xuan
    Ni, Haiwei
    Wang, Ting
    Zhao, Qiong
    Liu, Hai
    Xing, Yingying
    Xi, Tao
    Zheng, Lufeng
    EBIOMEDICINE, 2019, 49 : 389 - 390
  • [2] PD-L1/RelB axis regulated the stemness of breast cancer cells
    Choi, Hack S.
    Kim, Su L.
    Lee, Dong S.
    CANCER SCIENCE, 2024, 115 : 990 - 990
  • [3] MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells
    Zuo, Y.
    Zheng, W.
    Liu, J.
    Tang, Q.
    Wang, S. S.
    Yang, X. S.
    NEOPLASMA, 2020, 67 (01) : 93 - +
  • [4] MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells
    J Cui
    Y Yang
    H Li
    Y Leng
    K Qian
    Q Huang
    C Zhang
    Z Lu
    J Chen
    T Sun
    R Wu
    Y Sun
    H Song
    X Wei
    P Jing
    X Yang
    C Zhang
    Oncogene, 2015, 34 : 3895 - 3907
  • [5] Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells
    Zhang, Xiumei
    Zhang, Bingfeng
    Zhang, Panhong
    Lian, Lihui
    Li, Lianlian
    Qiu, Zhihong
    Qian, Kai
    Chen, An
    Liu, Qiongqing
    Jiang, Yinjie
    Cui, Jiajun
    Qi, Bing
    PLOS ONE, 2019, 14 (05):
  • [6] MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells
    Cui, J.
    Yang, Y.
    Li, H.
    Leng, Y.
    Qian, K.
    Huang, Q.
    Zhang, C.
    Lu, Z.
    Chen, J.
    Sun, T.
    Wu, R.
    Sun, Y.
    Song, H.
    Wei, X.
    Jing, P.
    Yang, X.
    Zhang, C.
    ONCOGENE, 2015, 34 (30) : 3895 - 3907
  • [7] HuR facilitates cancer stemness of lung cancer cells via regulating miR-873/CDK3 and miR-125a-3p/CDK3 axis
    Zhang, Yu
    Yang, Limin
    Ling, Chunhua
    Heng, Wei
    BIOTECHNOLOGY LETTERS, 2018, 40 (04) : 623 - 631
  • [8] HuR facilitates cancer stemness of lung cancer cells via regulating miR-873/CDK3 and miR-125a-3p/CDK3 axis
    Yu Zhang
    Limin Yang
    Chunhua Ling
    Wei Heng
    Biotechnology Letters, 2018, 40 : 623 - 631
  • [9] Erratum: MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells
    J Cui
    Y Yang
    H Li
    Y Leng
    K Qian
    Q Huang
    C Zhang
    Z Lu
    J Chen
    T Sun
    R Wu
    Y Sun
    H Song
    X Wei
    P Jing
    X Yang
    C Zhang
    Oncogene, 2015, 34 : 4018 - 4018
  • [10] Neutrophil elastase regulates PD-L1 expression in breast cancer
    Gall, Victor
    Philips, Anne V.
    Chawla, Akhil
    Qiao, Na
    St John, Lisa S.
    Sukhumalchandra, Pariya
    Zhang, Mao
    Molldrem, Jeffrey J.
    Alatrash, Gheath
    Mittendorf, Elizabeth A.
    CANCER RESEARCH, 2016, 76